BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 17589944)

  • 21. Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial).
    Maurel J; Sánchez-Cabús S; Laquente B; Gaba L; Visa L; Fabregat J; Povés I; Roselló S; Díaz-Beveridge R; Martín-Richard M; Rodriguez J; Sabater L; Conill C; Cambray M; Reig A; Ayuso JR; Valls C; Ferrández A; Bombí JA; Ginés A; García-Albéniz X; Fernández-Cruz L
    Cancer Chemother Pharmacol; 2018 Dec; 82(6):935-943. PubMed ID: 30225601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas.
    Spitz FR; Abbruzzese JL; Lee JE; Pisters PW; Lowy AM; Fenoglio CJ; Cleary KR; Janjan NA; Goswitz MS; Rich TA; Evans DB
    J Clin Oncol; 1997 Mar; 15(3):928-37. PubMed ID: 9060530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas.
    Blackstock AW; Tepper JE; Niedwiecki D; Hollis DR; Mayer RJ; Tempero MA
    Int J Gastrointest Cancer; 2003; 34(2-3):107-16. PubMed ID: 15361643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas.
    Ammori JB; Colletti LM; Zalupski MM; Eckhauser FE; Greenson JK; Dimick J; Lawrence TS; McGinn CJ
    J Gastrointest Surg; 2003; 7(6):766-72. PubMed ID: 13129554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma.
    Landry J; Catalano PJ; Staley C; Harris W; Hoffman J; Talamonti M; Xu N; Cooper H; Benson AB
    J Surg Oncol; 2010 Jun; 101(7):587-92. PubMed ID: 20461765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant treatment strategies for pancreatic cancer.
    Newman EA; Simeone DM; Mulholland MW
    J Gastrointest Surg; 2006 Jun; 10(6):916-26. PubMed ID: 16769552
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoadjuvant strategies for pancreatic cancer.
    Evans DB; Wolff RA; Crane CH
    Oncology (Williston Park); 2001 Jun; 15(6):727-37; discussion 741-4, 747. PubMed ID: 11430206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial.
    Small W; Berlin J; Freedman GM; Lawrence T; Talamonti MS; Mulcahy MF; Chakravarthy AB; Konski AA; Zalupski MM; Philip PA; Kinsella TJ; Merchant NB; Hoffman JP; Benson AB; Nicol S; Xu RM; Gill JF; McGinn CJ
    J Clin Oncol; 2008 Feb; 26(6):942-7. PubMed ID: 18281668
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas.
    Pipas JM; Mitchell SE; Barth RJ; Vera-Gimon R; Rathmann J; Meyer LP; Wagman RS; Lewis LD; McDonnell C; Colacchio TA; Perez RP
    Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1317-22. PubMed ID: 11483344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer.
    Crane CH; Janjan NA; Evans DB; Wolff RA; Ballo MT; Milas L; Mason K; Charnsangavej C; Pisters PW; Lee JE; Lenzi R; Vauthey JN; Wong A; Phan T; Nguyen Q; Abbruzzese JL
    Int J Pancreatol; 2001; 29(1):9-18. PubMed ID: 11560155
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma.
    Jin C; Yao L; Long J; Fu DL; Yu XJ; Xu J; Yang F; Ni QX
    Chin Med J (Engl); 2009 Feb; 122(3):284-90. PubMed ID: 19236805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas.
    White R; Lee C; Anscher M; Gottfried M; Wolff R; Keogan M; Pappas T; Hurwitz H; Tyler D
    Ann Surg Oncol; 1999; 6(1):38-45. PubMed ID: 10030414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
    Stokes JB; Nolan NJ; Stelow EB; Walters DM; Weiss GR; de Lange EE; Rich TA; Adams RB; Bauer TW
    Ann Surg Oncol; 2011 Mar; 18(3):619-27. PubMed ID: 21213060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas.
    Pingpank JF; Hoffman JP; Ross EA; Cooper HS; Meropol NJ; Freedman G; Pinover WH; LeVoyer TE; Sasson AR; Eisenberg BL
    J Gastrointest Surg; 2001; 5(2):121-30. PubMed ID: 11331473
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I-II trial of twice-weekly gemcitabine and concomitant irradiation in patients undergoing pancreaticoduodenectomy with extended lymphadenectomy for locally advanced pancreatic cancer.
    Joensuu TK; Kiviluoto T; Kärkkäinen P; Vento P; Kivisaari L; Tenhunen M; Westberg R; Elomaa I
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):444-52. PubMed ID: 15380578
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term effects of multimodal treatment for patients with resectable carcinoma of the pancreas.
    Okabayashi T; Nishimori I; Nishioka A; Yamashita K; Sugimoto T; Dabanaka K; Maeda H; Kohsaki T; Ogawa Y; Kobayashi M; Onishi S; Hanazaki K
    Oncol Rep; 2008 Sep; 20(3):651-6. PubMed ID: 18695919
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does intraoperative radiation therapy improve local tumor control in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma? A propensity score analysis.
    Showalter TN; Rao AS; Rani Anne P; Rosato FE; Rosato EL; Andrel J; Hyslop T; Xu X; Berger AC
    Ann Surg Oncol; 2009 Aug; 16(8):2116-22. PubMed ID: 19437078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome.
    Sasson AR; Wetherington RW; Hoffman JP; Ross EA; Cooper H; Meropol NJ; Freedman G; Pingpank JF; Eisenberg BL
    Int J Gastrointest Cancer; 2003; 34(2-3):121-8. PubMed ID: 15361645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial.
    Wei AC; Ou FS; Shi Q; Carrero X; O'Reilly EM; Meyerhardt J; Wolff RA; Kindler HL; Evans DB; Deshpande V; Misdraji J; Tamm E; Sahani D; Moore M; Newman E; Merchant N; Berlin J; Goff LW; Pisters P; Posner MC
    Ann Surg Oncol; 2019 Dec; 26(13):4489-4497. PubMed ID: 31418130
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant chemoradiation for non-metastatic pancreatic cancer increases margin-negative and node-negative rates at resection.
    Berriochoa CA; Abdel-Wahab M; Leyrer CM; Khorana A; Matthew Walsh R; Kumar AMS
    J Dig Dis; 2017 Nov; 18(11):642-649. PubMed ID: 29055078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.